Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLA5PR GLARS-NF1
- Development stage
- Phase 3
- Lead developer
- GL Pharm Tech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GLA5PR GLARS-NF1 is a controlled-release (CR) oral tablet formulation of pregabalin developed for once-daily administration. It is designed to provide sustained drug release using a three-layered tablet structure with high-viscosity polymer (PEO) in the upper and lower layers to regulate the release rate of pregabalin. The formulation aims to improve patient compliance by reducing dosing frequency compared to immediate-release pregabalin. Mechanistically, it acts as a modulator of the CACNA2D1 protein (the alpha-2-delta subunit of voltage-gated calcium channels), thereby reducing neurotransmitter release and alleviating neuropathic pain symptoms. Clinical studies have demonstrated that its efficacy and safety are non-inferior to immediate-release pregabalin for peripheral neuropathic pain, including diabetic peripheral neuropathy[1][2][4][6].
- Brand names
- GLA5PR GLARS-NF1GLA-5PR GLARS-NF1GLA 5PR GLARS-NF1
- Other names
- Pregabalin controlled releaseCR pregabalin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)
Beyond the preview
Go deeper on GLA5PR GLARS-NF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLA5PR GLARS-NF1.